The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. . Shareholders who ...

AbbVie Inc. has earned a spot among the elite Dividend Monarchs by raising dividends for 52 straight years—a feat worthy of a ...

A recent selloff of Neurocrine Biosciences stock feels unwarranted and may have created a contrarian buy opportunity. Learn ...

Shares of AbbVie Inc. ABBV shed 2.90% to $171.68 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and Dow ...

We recently published a list of the 10 Best Dividend Monarchs to Invest in Now. In this article, we are going to take a look ...

Yuflyma is a high-concentration and citrate-free formulation of Humira biosimilar, approved for multiple inflammatory ...

With broadcasts of the college football and NFL playoffs, as well as the men’s and women’s college basketball tournaments, many drugmakers looked to sports for advertising opportunities in Q1.

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), The TJX Companies, Inc ...

NEW YORK, NY / ACCESS Newswire / April 15, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and ...

We recently published a list of the 10 High Growth Forever Dividend Stocks to Invest In. In this article, we are going to ...

The 340B program requires drugmakers who want to participate in Medicaid and Medicare to discount their prices for hospitals, clinics and other providers that serve low-income patients. Those “covered ...

Tremfya achieved an impressions share of voice (SOV) of 3.35%, generating 2.1 billion total impressions. While the brand held the top spot, the total impressions dipped by 2 million from when Sanofi ...